Payment overview · 2025
General Payments
$29,415.56
27 reported records · 11 companies
Healthcare provider profile · identity verified
Gabriel Noah Mannis, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology · STANFORD, CA · NPI 1881929347
Verified facts
What the public records show
CMS Open Payments records show Gabriel Noah Mannis, MD received $29,415.56 in general payments during 2025 across 27 reported records.
ABBVIE INC. accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Inqovi, Vanflyta, Venclexta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Venclexta by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cresemba as an associated drug or biological on 2800 records involving 1563 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Cresemba by this doctor in 2024.
Daiichi Sankyo Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VANFLYTA as an associated drug or biological on 3187 records involving 1913 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vanflyta by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Venclexta by this doctor in 2024.
TAIHO ONCOLOGY, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INQOVI as an associated drug or biological on 4572 records involving 2852 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Inqovi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $9,290.39 | 31.6% | 10 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $3,900.00 | 13.3% | 1 | 2025 |
| Astellas Pharma Global Development | Unresolved — no canonical attribution shown | $3,718.00 | 12.6% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $3,392.95 | 11.5% | 4 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $2,658.89 | 9.0% | 3 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $2,340.00 | 8.0% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $1,847.32 | 6.3% | 2 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $800.00 | 2.7% | 1 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $685.00 | 2.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $676.00 | 2.3% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $107.01 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $27,876.50 | 15 |
| Food and Beverage | $854.06 | 11 |
| Honoraria | $685.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $6,080.58 | 7 | 2025 |
Source payment records
|
|||||
| Xospata Normalized: xospata |
Drug | Astellas Pharma Global Development, Astellas Pharma US Inc | $4,394.00 | 3 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $3,900.00 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $3,225.00 | 1 | 2025 |
Source payment records
|
|||||
| ELZONRIS Normalized: elzonris |
Drug | Stemline Therapeutics Inc. | $2,340.00 | 1 | 2025 |
Source payment records
|
|||||
| REVUFORJ Normalized: revuforj |
Drug | Syndax Pharmaceuticals, Inc. | $800.00 | 1 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $685.00 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $167.95 | 3 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $107.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INQOVI inqovi |
2025 | Inqovi | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Vanflyta vanflyta |
2025 | Vanflyta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
57 | 21 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Cresemba open payments reported associated product |
CMS Open Payments — General Payments 2800 supporting records · 1563 recipient NPIs · example record 1238560682 |
Cresemba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Daiichi Sankyo Inc. Exact reporting entity; no affiliate inference |
2025 | VANFLYTA open payments reported associated product |
CMS Open Payments — General Payments 3187 supporting records · 1913 recipient NPIs · example record 1197002053 |
Vanflyta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
57 | 21 |
| TAIHO ONCOLOGY, INC. Exact reporting entity; no affiliate inference |
2025 | INQOVI open payments reported associated product |
CMS Open Payments — General Payments 4572 supporting records · 2852 recipient NPIs · example record 1211403676 |
Inqovi · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Venclexta | Venetoclax | 57 | 21 |
| Inqovi | Decitabine/Cedazuridine | 18 | suppressed |
| Tibsovo | Ivosidenib | 18 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Cresemba | Isavuconazonium Sulfate | 11 | suppressed |
| Vanflyta | Quizartinib Dihydrochloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $29,415.56 · 27 records | ABBVIE INC. | DATROWAY, ELZONRIS, INQOVI, REBLOZYL, REVUFORJ, Rezlidhia, VENCLEXTA, Vanflyta, Xospata | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Inqovi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error